To include your compound in the COVID-19 Resource Center, submit it here.

Safinamide: Completed Phase III enrollment

The partners completed enrollment of 679 patients with early idiopathic PD in the double-blind, placebo-controlled,

Read the full 154 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE